Shares of Alvotech ALVO, a biotechnology company specializing in the development and manufacturing of biosimilar medicines, ...

REYKJAVIK, Iceland, June 4, 2026 - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the ...

On September 11, 2025, the U.S. Food and Drug Administration (FDA) issued new guidance for the development of therapeutic protein biosimilars, focusing on comparative analytical assessment and quality ...

Key Points Interested in Alvotech? Here are five stocks we like better. Alvotech said it is entering a "critical inflection ...

Tailored EMA and FDA pathways may waive comparative efficacy studies when analytical and functional similarity are convincingly demonstrated, while preserving clinical confirmation for ...

While the regulatory landscape around biosimilars is evolving to encourage efficiency and innovation, the commercial ...

The FDA has proposed new policies to speed up the development and lower the cost of biosimilar agents for cancer and other serious illnesses. These policies include “major updates to simplify ...

Entyvio is a biologic medicine approved for the treatment of adults with moderately to severely active ulcerative colitis and Crohn’s disease.

Please provide your email address to receive an email when new articles are posted on . The FDA issued draft guidance that would streamline testing of biosimilars. A separate plan would eliminate ...

Currently, the global biosimilars market includes monoclonal antibody (mAb) biosimilars, insulins, interferons, erythropoietins, filgrastim, somatropin and follicle-stimulating hormone. Of these, the ...

A new independent analysis of the US Food and Drug Administration's (FDA) workload around biosimilars over the first three years shows how biosimilar development has slowly progressed as companies ...